Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis

A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies

(2018) Yoshinori Takeuchi et al.   BMC Medical Research Methodology

Using the Symmetry Analysis Design to Screen for Adverse Effects of Non-vitamin K Antagonist Oral Anticoagulants

(2018) Maja Hellfritzsch et al.   DRUG SAFETY

Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies

(2017) Edward Chia-Cheng Lai et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation

(2017) Alvaro Alonso et al.   HEART

Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity

(2017) Rigas G. Kalaitzidis et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Postapproval Observational Studies of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation

(2017) Tatjana S. Potpara et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study

(2017) Antonios Douros et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study

(2017) Géric Maura et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology

(2017) Julien Bezin et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France

(2017) P. Tuppin et al.   REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE

The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic

(2016) Faris Al-Khalili et al.   CURRENT MEDICAL RESEARCH AND OPINION

Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies

(2016) Emanuel Raschi et al.   DRUG SAFETY

Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation

(2016) Jan Beyer-Westendorf et al.   EUROPACE

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

(2016) Paulus Kirchhof et al.   EUROPEAN HEART JOURNAL

Novel oral anticoagulant drugs and severe oesophagitis dissecans

(2016) R. Cox et al.   INTERNAL MEDICINE JOURNAL

Dabigatran-induced esophagitis: A frequently overlooked adverse effect

(2016) Nixiao Zhang et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Apixaban-induced hepatotoxicity

(2016) Mihaela Cordeanu et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Universalism, Responsiveness, Sustainability — Regulating the French Health Care System

(2016) Monika Steffen   NEW ENGLAND JOURNAL OF MEDICINE

Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database

(2016) Line Sahli et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation

(2016) J. Hecker et al.   THROMBOSIS AND HAEMOSTASIS

Factors Driving Anticoagulant Selection in Patients With Atrial Fibrillation in the United States

(2015) Julie C. Lauffenburger et al.   AMERICAN JOURNAL OF CARDIOLOGY

National Trends in Ambulatory Oral Anticoagulant Use

(2015) Geoffrey D. Barnes et al.   AMERICAN JOURNAL OF MEDICINE

Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system

(2015) Emanuel Raschi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K AntagonistsCLINICAL PERSPECTIVES

(2015) Géric Maura et al.   CIRCULATION

Hepatotoxicity of New Oral Anticoagulants (NOACs)

(2015) Evangelia Liakoni et al.   DRUG SAFETY

Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry

(2015) J. Beyer-Westendorf et al.   EUROPACE

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

(2015) Hein Heidbuchel et al.   EUROPACE

Positive Predictive Value of French Hospitalization Discharge Codes for Stroke and Transient Ischemic Attack

(2015) Maurice Giroud et al.   EUROPEAN NEUROLOGY

Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs

(2015) Freek W A Verheugt et al.   LANCET

Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries

(2015) Nicole Pratt et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis

(2015) Daniel Caldeira et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation— Quality and Cost Implications

(2014) Nihar R. Desai et al.   AMERICAN JOURNAL OF MEDICINE

Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013

(2014) J. B. Olesen et al.   EUROPACE

Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis

(2014) Daniel Caldeira et al.   HEART

Anticoagulation in atrial fibrillation

(2014) B. A. Steinberg et al.   BMJ-British Medical Journal

Symptomatic Hepatocellular Liver Injury With Hyperbilirubinemia in Two Patients Treated With Rivaroxaban

(2014) Evangelia Liakoni et al.   JAMA Internal Medicine

Worldwide Epidemiology of Atrial Fibrillation

(2013) Sumeet S. Chugh et al.   CIRCULATION

Adherence to anticoagulant treatment with dabigatran in a real-world setting

(2013) S. Schulman et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

(2013) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection

(2013) Izyan A. Wahab et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Rivaroxaban

(2012) Sean T. Duggan   American Journal of Cardiovascular Drugs

National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011

(2012) Kate Kirley et al.  

Dabigatran-Induced Acute Hepatitis

(2012) Bram Rochwerg et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Gastrointestinal disorders and dabigatran

(2012) Arthur Hoffman et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

(2009) Sam Schulman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis

(2009) Ioannis Tsiropoulos et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY